Stemcell Technologies


STEMCELL Technologies Inc., often abbreviated to STEMCELL, is a Canadian biotechnology company that develops, manufactures, and sells scientific instruments, reagents, and consumables.[1][2] The company also markets education, custom manufacturing, and contract assay services for academic and industrial scientists.

STEMCELL Technologies
TypePrivate
IndustryBiotechnology
Founded1993
FounderAllen Eaves
Headquarters
Vancouver, British Columbia
,
Canada
Key people
Allen Eaves, Chairman & CEO
Number of employees
> 2000
Websitestemcell.com

The company has offices in the United States, Europe, Asia, and Australia with the headquarter being in Vancouver, British Columbia, Canada. The company distributes products to approximately 120 countries.[1][3] Dr. Allen Eaves, the founder, currently serves as the President and CEO.

History

Allen Eaves (MD, PhD, FRCPC), a hematologist and cancer researcher, co-founded the Terry Fox Laboratory (TFL) in Vancouver with his wife, hematologist and cancer researcher, Dr. Connie Eaves, in 1981. Allen Eaves’ research group at the TFL made their own standardized cell culture medium for growing hematopoietic stem cells in the lab. To help fund his blood cancer research program at the TFL, Eaves started selling this medium—named MethoCult™—to other research groups around the world. Eventually, the demand for MethoCult™ surpassed the capacity of Eaves’ research lab and the TFL. With a loan from Western Economic Diversification Canada and a mortgage on his house, Eaves purchased the business from the TFL and launched STEMCELL Technologies Inc. as an independent company on July 2, 1993.[4]

Since its launch, STEMCELL’s products have expanded to include specialized cell culture and cell separation technologies and services used in stem cell, immunology, cancer, regenerative medicine, and cellular therapy research.

In 2018, STEMCELL received a $45 million grant from the Canadian and British Columbian governments toward building an Advanced Biologicals Manufacturing Facility (ABMF) in Burnaby, British Columbia.[5][6][7] The ABMF will enable the scale-up of product manufacturing under good manufacturing practice (GMP) guidelines, to support the development of regenerative medicine and cell therapy products used in clinical trials.[5]

References
  1. "Spotlight: STEMCELL Technologies". CME. Retrieved 1 March 2022.
  2. "Improving the efficiency and accuracy of cell research". nrc.canada.ca. 10 December 2021. Retrieved 1 March 2022.
  3. "B.C.'s 'world-class' biotech sector plays key role in developing COVID-19 treatments and vaccines". Vancouver Sun. Retrieved 1 March 2022.
  4. "Meet Allen Eaves: Academic Biologist turned CEO | Eurostemcell". www.eurostemcell.org. Retrieved 1 March 2022.
  5. "Federal and provincial governments support creation of biotech manufacturing facility in the Lower Mainland". www.canada.ca. 25 April 2018. Retrieved 1 March 2022.
  6. "Hundreds of new jobs expected as B.C. biotech firm plans new facility". cbc.ca. Retrieved 2 March 2022.
  7. "Burnaby tech company gets $45 million". Burnaby Now. Retrieved 2 March 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.